Smart Insulin Pens Market to Experience Great Progress with the launch of New Smart Insulin Pen Device
Posted On April 28, 2021
Insulin was invented for therapeutic purposes more than 100 years ago. Since then, there have been great innovations in the field of diabetes so that patients and their family members can live a normal life while combating the disease.
Another bid development in this sector comes with the launch of Mallya in France. It is a medical device that will become available in pharmacies across the country. The new device might bring a great boost for Smart Insulin Pens Market as it comes with the capability to collects and transfers insulin data with almost 100 percent precision. The Insulin Pen can be easily recharged through a USB port and is compatible with most insulin pens. The innovation is also likely to positively affect Diabetes Pen Market as its objective is to make patients' daily lives easier while they are undergoing insulin therapy.
The device has been made with the collaboration of two companies. One of them is BIOCORP, a French company known for its development, design, and manufacturing of next-generation medical devices. The other one is Roche Diabetes Care France, a reference company whose goal is to support patients suffering from diabetes. They announced their collaboration in June 2020 and have started sending out Mallaya smart devices for insulin injection pens from April 2021. The most noteworthy aspect of this innovation is that it has received CE-mark (medical device) and is the first in its category to have gotten it.
The device is reusable and compatible with 91 percent of disposable insulin pens; Mallya collects insulin data automatically and sends it to the Gluci-Chek application developed by Roche Diabetes Care France.
The Novel Insulin Pen Device facilitates the transmission of verified information on which patients can depend, and a doctor can make his decisions. With this integration, the patients might benefit from the solutions that aim at lessening the mental burden of their ailment.
Mallya gathers and transfers insulin data in real-time on the user's smartphone. After installing the device, patients can resume their insulin schedule as usual, with the data is automatically sent by the device. It is reported that, with the advent of Coronavirus, 37% of diabetic patients have seen an increase in their anxiety. This is where the new device helps them follow the evolution of their disease. Thus, the device is expected to provide better serenity, security, and less error in terms of diabetic patients and their treatments.
France has been ruthlessly combating the second wave of the pandemic, with most people confined to their homes. In such a scenario, diabetic patients are likely to feel that they are not getting proper treatment and attention for their disease. Hence, the new connected device can reduce such tensions with real close monitoring.